Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 771-775

  Kikuchi, Kiyoshi ^a   Kawahara, Ko Ichi ^b   Uchikado, Hisaaki ^g   Miyagi, Naohisa ^a   Kuramoto, Terukazu ^h   Miyagi, Tomoya ^h   Morimoto, Yoko ^d   Ito, Takashi ^b   Tancharoen, Salunya ⁱ   Miura, Naoki ^e   Takenouchi, Kazunori ^b   Oyama, Yoko ^b   Shrestha, Binita ^b   Matsuda, Fumiyo ^f   Yoshida, Yoshihiro ^f   Arimura, Shinihiro ^c   Mera, Kentaro ^d   Tada, Ko Ichi ^d   Yoshinaga, Narimasa ^b   Maenosono, Ryuichi ^b   Ohno, Yoshiko ^b   Hashiguchi, Teruto ^b   Maruyama, Ikuro ^b   Shigemori, Minoru ^g   more..

^a Yame General Hospital   (Japan)

^b Division of Laboratory and Vascular Medicine   (Japan)

^c Field of Oral and Maxillofacial Rehabilitation ^*  (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Omuta City General Hospital   (Japan)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Cerebral infarction; Edaravone; Free radical scavenger; Neurologic disease; Neuroprotection

Indexed keywords

HYDROXYL RADICAL; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NORPHENAZONE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN TUMOR; DEGENERATIVE DISEASE; DRUG DIFFUSION; DRUG EFFECT; DRUG EFFICACY; HUMAN; INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; SPINAL CORD INJURY; SPINAL CORD ISCHEMIA; STROKE; TRAUMATIC BRAIN INJURY;

EID: 79960267924     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.281     Document Type: Article

References (60)

1. Adams HP Jr, del Zoppo G, Alberts MJ, et al: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655-1711, 2007.
2. Kikuchi K, Kawahara K, Tancharoen S, et al: The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 329: 865-874, 2009.
3. Kikuchi K, Tancharoen S, Matsuda F, et al: Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 390: 1121-1125, 2009.
4. Higashi Y, Jitsuiki D, Chayama K and Yoshizumi M: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger for treatment of cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 1: 85-93, 2006.
5. Lapchak PA and Zivin JA: The lipophilic multifunctional antioxidant edaravone (Radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 215: 95-100, 2009.
6. Wang CX and Shuaib A: Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 24: 537-546, 2007.
7. Green AR and Shuaib A: Therapeutic strategies for the treatment of stroke. Drug Discov Today 11: 681-693, 2006.
8. Van der Worp HB, Kappelle LJ, Algra A, et al: The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology 58: 133-135, 2002.
9. Shuaib A, Lees KR, Lyden P, et al: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562-571, 2007.
10. Edaravone Acute Infarction Study Group: Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15: 222-229, 2003.
11. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y and Urabe T: Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36: 2220-2225, 2005.
12. Unno Y, Katayama M and Shimizu H: Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. Clin Drug Investig 30: 143-155, 2010.
13. Papadopoulos MC, Krishna S and Verkman AS: Aquaporin water channels and brain edema. Mt Sinai J Med 69: 242-248, 2002.
14. Yagi K, Kitazato KT, Uno M, et al: Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 40: 626-631, 2009.
15. Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N and Tada N: Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 12: 9-20, 2006.
16. Feigin VL and Findlay M: Advances in subarachnoid hemorrhage. Stroke 37: 305-308, 2006.
17. Van Gijn J, Kerr RS and Rinkel GJ: Subarachnoid haemorrhage. Lancet 369: 306-318, 2007.
18. Wiebers DO, Whisnant JP, Huston J III, et al: Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362: 103-110, 2003.
19. Aoki T, Nishimura M, Kataoka H, Ishibashi R, Nozaki K and Hashimoto N: Reactive oxygen species modulate growth of cerebral aneurysms: a study using the free radical scavenger edaravone and p47phox(-/-) mice. Lab Invest 89: 730-741, 2009.
20. Dorsch NW and King MT: A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: incidence and effects. J Clin Neurosci 1: 19-26, 1994.
21. Nakagomi T, Yamakawa K, Sasaki T, Saito I and Takakura K: Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 12: 17-21, 2003.
22. Munakata A, Ohkuma H, Nakano T, Shimamura N, Asano K and Naraoka M: Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 64: 423-429, 2009.
23. Tosaka M, Hashiba Y, Saito N, Imai H, Shimizu T and Sasaki T: Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. Acta Neurochir 144: 1305-1310, 2002.
24. Nakamura T, Kuroda Y, Yamashita S, et al: Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 39: 463-469, 2008.
25. Fayad PB and Awad IA: Surgery for intracerebral hemorrhage. Neurology 51: S69-S73, 1998.
26. McDonald JW and Sadowsky C: Spinal-cord injury. Lancet 359: 417-425, 2002.
27. Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000.
28. Ao Q, Wang AJ, Chen GQ, Wang SJ, Zuo HC and Zhang XF: Combined transplantation of neural stem cells and olfactory ensheathing cells for the repair of spinal cord injuries. Med Hypotheses 69: 1234-1237, 2007.
29. Rosenfeld JV, Bandopadhayay P, Goldschlager T and Brown DJ: The ethics of the treatment of spinal cord injury: stem cell transplants, motor neuroprosthetics, and social equity. Top Spinal Cord Inj Rehabil 14: 76-88, 2008.
30. Aoyama T, Hida K, Kuroda S, et al: Edaravone (MCI-186) scavenges reactive oxygen species and ameliorates tissue damage in the murine spinal cord injury model. Neurol Med Chir 48: 539-545, 2008.
31. Suzuki K, Kazui T, Terada H, et al: Experimental study on the protective effects of edaravone against ischemic spinal cord injury. J Thorac Cardiovasc Surg 130: 1586-1592, 2005.
32. Takahashi G, Sakurai M, Abe K, Itoyama Y and Tabayashi K: MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits. J Thorac Cardiovasc Surg 126: 1461-1466, 2003.
33. Takahashi G, Sakurai M, Abe K, Itoyama Y and Tabayashi K: MCI-186 reduces oxidative cellular damage and increases DNA repair function in the rabbit spinal cord after transient ischemia. Ann Thorac Surg 78: 602-607, 2004.
34. Ohta S, Iwashita Y, Takada H, Kuno S and Nakamura T: Neuroprotection and enhanced recovery with edaravone after acute spinal cord injury in rats. Spine 30: 1154-1158, 2005.
35. Maas AI, Stocchetti N and Bullock R: Moderate and severe traumatic brain injury in adults. Lancet Neurol 7: 728-741, 2008.
36. Greenwald BD, Burnett DM and Miller MA: Congenital and acquired brain injury. 1. Brain injury: epidemiology and pathophysiology. Arch Phys Med Rehabil 84: S3-S7, 2003.
37. Chirumamilla S, Sun D, Bullock MR and Colello RJ: Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. J Neurotrauma 19: 693-703, 2002.
38. Rice AC, Khaldi A, Harvey HB, et al: Proliferation and neuronal differentiation of mitotically active cells following traumatic brain injury. Exp Neurol 183: 406-417, 2003.
39. Itoh T, Satou T, Nishida S, et al: Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neurochem Res 35: 348-355, 2009.
40. Itoh T, Satou T, Nishida S, Tsubaki M, Hashimoto S and Ito H: The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. Neurotox Res 16: 378-389, 2009.
41. Dohi K, Satoh K, Mihara Y, et al: Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma 23: 1591-1599, 2006.
42. Dohi K, Satoh K, Nakamachi T, et al: Does edaravone (MCI- 186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury? Antioxid Redox Signal 9: 281-287, 2007.
43. Raibon E, Todd LM and Moller T: Glial cells in ALS: the missing link? Phys Med Rehabil Clin N Am 19: 441-459, 2008.
44. Mitchell JD and Borasio GD: Amyotrophic lateral sclerosis. Lancet 369: 2031-2041, 2007.
45. Rosen DR, Siddique T, Patterson D, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62, 1993.
46. Ito H, Wate R, Zhang J, et al: Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213: 448-455, 2008.
47. Kabashi E and Durham HD: Failure of protein quality control in amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1038-1050, 2006.
48. Valentine JS and Hart PJ: Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 100: 3617-3622, 2003.
49. Yoshino H and Kimura A: Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7: 241-245, 2006.
50. Takahashi R: Edaravone in ALS. Exp Neurol 217: 235-236, 2009.
51. De Lau LM and Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535, 2006.
52. Yuan WJ, Yasuhara T, Shingo T, et al: Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci 9: 75, 2008.
53. Ma L, Cao TT, Kandpal G, et al: Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation. Neurochem Res 35: 130-142, 2010.
54. Rosati G: The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117-139, 2001.
55. Cohen JA: Emerging therapies for relapsing multiple sclerosis. Arch Neurol 66: 821-828, 2009.
56. Motomura K, Ogura M, Natsume A, Yokoyama H and Wakabayashi T: A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation. Neurosci Lett 485: 65-70, 2010.
57. Anderson VA, Godber T, Smibert E, Weiskop S and Ekert H: Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer 82: 255-262, 2000.
58. Crossen JR, Garwood D, Glatstein E and Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627-642, 1994.
59. Monje ML and Palmer T: Radiation injury and neurogenesis. Curr Opin Neurol 16: 129-134, 2003.
60. Ishii J, Natsume A, Wakabayashi T, et al: The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress. Neurosci Lett 423: 225-230, 2007.